Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

AbstractObjective This study evaluated the clinical efficacy and safety of interleukin-1 (IL-1) blockade for patients with COVID-19.Methods The PubMed, Web of Science, Ovid Medline, Embase and Cochrane Library databases were searched for relevant articles from their inception to 25 September 2022. O...

Full description

Bibliographic Details
Main Authors:	Shao-Huan Lan, Chi-Kuei Hsu, Shen-Peng Chang, Li-Chin Lu, Chih-Cheng Lai
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Annals of Medicine
Subjects:	Anakinra canakinumab COVID-19 interleukin-1 SARS-CoV-2
Online Access:	https://www.tandfonline.com/doi/10.1080/07853890.2023.2208872

Similar Items

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
by: Athina Dimosiari, et al.
Published: (2023-02-01)

Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children
by: Sara Signa, et al.
Published: (2020-06-01)

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
by: Antonio Vitale, et al.
Published: (2016-10-01)

The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review
by: Véronique Hentgen, et al.
Published: (2020-05-01)

Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study
by: Serena Colafrancesco, et al.
Published: (2017-06-01)

Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders
by: Dennis D. Arnold, et al.
Published: (2022-07-01)

Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review
by: Naomi Schlesinger, et al.
Published: (2023-07-01)

The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome
by: Chloé Challamel, et al.
Published: (2022-09-01)

Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
by: Serena Colafrancesco, et al.
Published: (2019-12-01)

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
by: Elke Lainka, et al.
Published: (2021-03-01)

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023-12-01)

An Unusual Case of Allergic Reaction to Anakinra in a Patient with Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS) and Subsequent Canakinumab Treatment
by: Marta Mejias Trueba, et al.
Published: (2020-07-01)

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
by: Jurgen Sota, et al.
Published: (2019-01-01)

A Systematic Review of the Safety of Blocking the IL-1 System in Human Pregnancy
by: Marie-Eve Brien, et al.
Published: (2021-12-01)

Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?
by: Hana Malcova, et al.
Published: (2021-01-01)

Therapy resistant urticaria as a long-term symptom of an incomplete Schnitzler syndrome
by: Viktoria Puxkandl, et al.
Published: (2023-07-01)

IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives
by: Hana Malcova, et al.
Published: (2021-02-01)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
by: Emanuel Della-Torre, et al.
Published: (2021-04-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

The role of interleukin 1 in the development of human diseases
by: E. L. Nasonov
Published: (2019-04-01)

Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
by: Ali Şahin, et al.
Published: (2020-01-01)

Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors
by: Sara Bindoli, et al.
Published: (2023-07-01)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
by: Alessandro Tomelleri, et al.
Published: (2018-06-01)

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience
by: Lingzhi Qiu, et al.
Published: (2024-03-01)

Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
by: Riccardo Papa, et al.
Published: (2020-07-01)

IL-1 inhibition in systemic juvenile idiopathic arthritis
by: Gabriella Giancane, et al.
Published: (2016-12-01)

FAMILIAL MEDITERRANEAN FEVER: ASSESSING THE OVERALL CLINICAL IMPACT AND FORMULATING TREATMENT PLANS
by: Donato Rigante, et al.
Published: (2019-04-01)

Fighting autoinflammation in FIRES: The role of interleukins and early immunomodulation
by: Marco Perulli, et al.
Published: (2022-01-01)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
by: Madelyn Espinosa-Cotton, et al.
Published: (2019-03-01)

Role of interleukin 1 in the development of atherosclerosis
by: E. L. Nasonov, et al.
Published: (2019-04-01)

The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives
by: Toplak N, et al.
Published: (2018-06-01)

Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents
by: Giorgio Costagliola, et al.
Published: (2021-05-01)

Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide
by: Alessandra Soriano, et al.
Published: (2020-06-01)

Therapy with canakinumab for gout
by: M. S. Eliseev, et al.
Published: (2019-04-01)

Differential Response to Interleukin‐1 Blockade With Anakinra on Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction Stratified According to Left Ventricular Ejection Fraction
by: Michele Golino, et al.
Published: (2023-09-01)

Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA
by: Francisco Gómez-García, et al.
Published: (2018-11-01)

Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study
by: Benjamin Van Tassell, et al.
Published: (2022-06-01)

IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis
by: N. Vergis, et al.
Published: (2021-11-01)

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study
by: Ekaterina Alexeeva, et al.
Published: (2023-11-01)

Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review
by: Rosa Talerico, et al.
Published: (2020-05-01)